Melanie Stein, ND Clinical improvement in treatment-refractory MCAS with normal conventional biomarkers and profound oral ...

Barzolvolimab improved symptoms in chronic spontaneous urticaria, supporting mast cell targeting as a novel treatment strategy. Read more.

According to an international multicenter study, CD2-negative mast cells are associated with significantly reduced overall survival in patients with SM. Patients with CD2-negative mast cells have ...

Many patients who call requesting an initial psychiatric consultation are suffering from a common condition known as mast cell activation syndrome (MCAS). MCAS can present with extremely diverse ...

Known for their role in allergic reactions, mast cells have long been recognised as key players in our immune system. When they encounter allergens, they release chemicals that trigger typical allergy ...

This scanning electron microscopy image captures the moment where degranulating mast cells (pseudo-colored in sepia) attract and start to incorporate living neutrophils (pseudo-colored in cyan), ...

Systemic mastocytosis (SM) is a rare blood disorder in which the body produces too many mast cells. Part of the immune response, mast cells are a type of white blood cell that releases histamine in ...

Blueprint Medicines’ focus on Ayvakit continues to pay off, which has ample untapped revenue potential in advanced and indolent systemic mastocytosis. Additionally, their pipeline includes other ...